KDNY Past Earnings image   This KDNY past earnings page last updated 8/21/2023
KDNY Past Earnings
PeriodPast Earnings DateGAAP
Q1 20235/9/2023-0.850
Q4 20222/27/2023-0.900
Q3 202211/10/2022-0.830
Q2 20228/8/2022-0.610
Q1 20225/12/2022-0.540
Q4 20213/17/20220.140
Q3 202111/8/2021-0.690
Q2 20218/12/2021-0.970
Q1 20215/12/2021-0.880
Q4 20204/7/2021-1.240
Q2 20208/3/2020-1.050
Q1 20205/4/2020-0.450
Q4 20193/9/2020-1.200
Q3 201911/7/2019-1.300
Q2 20198/1/2019-1.150
Q1 20195/7/2019-1.450
Q4 20182/27/2019-1.400
Q3 201810/30/2018-1.450
Q2 20188/1/2018-1.550
Q1 20185/2/2018-1.400
Q4 20173/1/2018-1.700
Q3 201710/31/2017-1.650
Q2 20178/2/2017-1.350
Q1 20175/2/2017-1.600
Q4 20163/1/2017-2.200
Q3 201611/3/2016-2.700
Q2 20168/3/20160.150
Q1 20165/2/2016-2.250
Q4 20153/8/20160.200
Q3 201511/23/20150.050
Q2 20158/10/2015-2.500
Q1 20155/28/2015-199.850
KDNY Past Revenue
PeriodPast Earnings DateGAAP
Q1 20235/9/20230.00B
Q4 20222/27/20230.00B
Q3 202211/10/20220.00B
Q2 20228/8/20220.00B
Q1 20225/12/20220.00B
Q4 20213/17/20220.05B
Q3 202111/8/20210.00M
Q2 20218/12/20210.03M
Q1 20215/12/20210.00B
Q4 20204/7/20210.00B
Q2 20208/3/20200.01B
Q1 20205/4/20200.01B
Q4 20193/9/20200.00B
Q3 201911/7/20190.00B
Q2 20198/1/20190.00B
Q1 20195/7/20190.00B
Q4 20182/27/20192.76M
Q3 201810/30/20183.06M
Q2 20188/1/20182.64M
Q1 20185/2/20186.63M
Q4 20173/1/20183.76M
Q3 201710/31/20173.79M
Q2 20178/2/20175.92M
Q1 20175/2/20173.77M
Q4 20163/1/20173.88M
Q3 201611/3/20163.79M
Q2 20168/3/201638.98M
Q1 20165/2/20164.03M
Q4 20153/8/201634.38M
Q3 201511/23/201519.15M
Q2 20158/10/20159.88M
Q1 20155/28/20159.57M
Quotes delayed 20 minutes

Email EnvelopeFree KDNY Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Chinook Therapeutics (KDNY) is categorized under the Healthcare sector; to help you further research past earnings across stocks, below are some other companies in the same sector:

KEQU Past Earnings
KIDS Past Earnings
KIN Past Earnings
KLDO Past Earnings
KMPH Past Earnings
KNTE Past Earnings
KOD Past Earnings
KPRX Past Earnings
KPTI Past Earnings
KRBP Past Earnings

KDNY Past Earnings Q&A

What was the best and worst KDNY past earnings results?
For Chinook Therapeutics, I'm wondering what the company's very best and worst earnings results have been, on an earnings per share basis?

✔️Accepted answer: The highest KDNY past earnings result in our data set was 0.200/share posted in Q4 2015, while the lowest was in Q1 2015 when KDNY posted -199.850/share.

  Suggested answer: The biggest top line earnings performance — aka revenue — quarter was in Q4 2021 when KDNY reported 0.05B in revenue, while the quarter with the lowest revenue in our data set was Q3 2021 at 0.00M of revenue.

  Suggested answer: There are 32 KDNY past earnings results in our data set.

On this page we presented the KDNY past earnings date information for Chinook Therapeutics. Reviewing that KDNY Past Earnings for the company, we see that the highest past earnings result in our data set was in Q4 2015, when KDNY posted gaap of 0.200/share. Meanwhile the lowest KDNY past earnings result was in Q1 2015, when KDNY posted gaap of -199.850/share. Turning to top line revenue performance, the biggest revenue quarter in our data set was seen in Q4 2021 when KDNY reported 0.05B in revenue, while the smallest revenue quarter was Q3 2021 when KDNY reported 0.00M in revenue.

Any self directed investor doing their due diligence on KDNY or any other given stock can benefit from researching all of the Chinook Therapeutics past earnings — and here, we present each quarter's result all together on one page for easy comparison. Studying this information can help when projecting future earnings, as well as determining whether the past earnings trajectory justifies the current stock value. That's why we bring you PastEarnings.com to make it easy for investors to investigate Chinook Therapeutics past earnings, or the past earnings information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for KDNY. Thanks for visiting, and the next time you need to research KDNY past earnings or those of another stock, we hope you'll think of our site, as your go-to past earnings research resource of choice.

Recommended: Top Ten Hedge Funds Holding PGLC, MGK YTD Return, Top Ten Hedge Funds Holding DRE.


KDNY Past Earnings | www.PastEarnings.com | Copyright © 2020 - 2023, All Rights Reserved

Nothing in PastEarnings.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
Wait! Don't leave yet.
Want to receive our latest research absolutely free?

Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 7.8%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 7.8%.